Cara Marks

1.8k total citations
16 papers, 1.5k citations indexed

About

Cara Marks is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Cara Marks has authored 16 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 4 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Oncology. Recurrent topics in Cara Marks's work include Glycosylation and Glycoproteins Research (4 papers), Biochemical and Structural Characterization (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Cara Marks is often cited by papers focused on Glycosylation and Glycoproteins Research (4 papers), Biochemical and Structural Characterization (4 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Cara Marks collaborates with scholars based in United States, Canada and Sweden. Cara Marks's co-authors include James D. Marks, Raymond C. Stevens, Stephen K. Anderson, Kenneth E. Goodwill, Paul F. Fitzpatrick, Reetta Raag, A. Bruce Montgomery, Joan Turner, John F. Murray and Craig A. Metz and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Cara Marks

16 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cara Marks United States 13 925 524 245 130 122 16 1.5k
David Chang United States 17 729 0.8× 301 0.6× 803 3.3× 164 1.3× 315 2.6× 32 2.2k
B Adamczyk Ireland 22 1.5k 1.6× 555 1.1× 556 2.3× 53 0.4× 104 0.9× 46 1.9k
Jiang Wu United States 20 1.1k 1.2× 188 0.4× 145 0.6× 58 0.4× 128 1.0× 43 1.8k
Stephen Thompson United Kingdom 23 923 1.0× 342 0.7× 312 1.3× 259 2.0× 152 1.2× 77 1.8k
G.J. Howlett Australia 20 841 0.9× 157 0.3× 79 0.3× 80 0.6× 84 0.7× 34 1.3k
Michael Burgess United States 14 1.9k 2.1× 244 0.5× 166 0.7× 90 0.7× 274 2.2× 17 2.6k
Helena Block Germany 20 809 0.9× 168 0.3× 523 2.1× 90 0.7× 130 1.1× 46 1.6k
David J. Ashline United States 22 1.6k 1.7× 551 1.1× 575 2.3× 84 0.6× 53 0.4× 32 2.4k
R T Ogata United States 20 771 0.8× 140 0.3× 342 1.4× 63 0.5× 127 1.0× 31 1.4k
Takashi Ohkura Japan 27 2.0k 2.2× 311 0.6× 771 3.1× 136 1.0× 135 1.1× 63 2.6k

Countries citing papers authored by Cara Marks

Since Specialization
Citations

This map shows the geographic impact of Cara Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cara Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cara Marks more than expected).

Fields of papers citing papers by Cara Marks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cara Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cara Marks. The network helps show where Cara Marks may publish in the future.

Co-authorship network of co-authors of Cara Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Cara Marks. A scholar is included among the top collaborators of Cara Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cara Marks. Cara Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Barbour, Abdelahhad, Leif Smith, Cara Marks, et al.. (2023). Discovery of phosphorylated lantibiotics with proimmune activity that regulate the oral microbiome. Proceedings of the National Academy of Sciences. 120(22). e2219392120–e2219392120. 13 indexed citations
2.
Barbour, Abdelahhad, Chunxiang Sun, Noah Fine, et al.. (2022). The Effect of Intensity-Modulated Radiotherapy to the Head and Neck Region on the Oral Innate Immune Response and Oral Microbiome: A Prospective Cohort Study of Head and Neck Tumour Patients. International Journal of Molecular Sciences. 23(17). 9594–9594. 14 indexed citations
3.
Moor, Anne C.E., et al.. (2001). Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library. Journal of Immunological Methods. 248(1-2). 17–30. 86 indexed citations
4.
Knight, A.R., C Hartnett, Cara Marks, et al.. (1998). Molecular size of recombinant alpha1beta1 and alpha1beta1gamma2 GABAA receptors expressed in Sf9 cells.. PubMed. 6(1). 1–18. 5 indexed citations
5.
Goodwill, Kenneth E., et al.. (1997). Crystal structure of tyrosine hydroxylase at 2.3 Å and its implications for inherited neurodegenerative diseases. Nature Structural Biology. 4(7). 578–585. 225 indexed citations
6.
Marks, Cara & James D. Marks. (1996). Phage Libraries — A New Route to Clinically Useful Antibodies. New England Journal of Medicine. 335(10). 730–733. 69 indexed citations
7.
Schier, Robert, Adrian M. McCall, Gregory P. Adams, et al.. (1996). Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site. Journal of Molecular Biology. 263(4). 551–567. 304 indexed citations
8.
Patten, Phillip A., Nathanael S. Gray, Priscilla L. Yang, et al.. (1996). The Immunological Evolution of Catalysis. Science. 271(5252). 1086–1091. 183 indexed citations
9.
Kosen, Phyllis Anne, Cara Marks, Arnold M. Falick, Stephen K. Anderson, & Irwin D. Kuntz. (1992). Disulfide bond-coupled folding of bovine pancreatic trypsin inhibitor derivatives missing one or two disulfide bonds. Biochemistry. 31(25). 5705–5717. 12 indexed citations
11.
Castro, Maria António, Cara Marks, Björn Nilsson, & Stephen K. Anderson. (1990). Does the Kunitz domain from the Alzheimer's amyloid β protein precursor inhibit a kallikrein responsible for post‐translational processing of nerve growth factor precursor?. FEBS Letters. 267(2). 207–212. 14 indexed citations
12.
Hurle, Mark R., Cara Marks, Phyllis Anne Kosen, S.M. Anderson, & Irwin D. Kuntz. (1990). Denaturant-dependent folding of bovine pancreatic trypsin inhibitor mutants with two intact disulfide bonds. Biochemistry. 29(18). 4410–4419. 33 indexed citations
13.
Marks, Cara, Hossein Naderi‐Manesh, Phyllis Anne Kosen, Irwin D. Kuntz, & Stephen K. Anderson. (1987). Mutants of Bovine Pancreatic Trypsin Inhibitor Lacking Cysteines 14 and 38 Can Fold Properly. Science. 235(4794). 1370–1373. 62 indexed citations
14.
Marks, Cara, Mark Vasser, Peter Ng, William J. Henzel, & Stephen K. Anderson. (1986). Production of native, correctly folded bovine pancreatic trypsin inhibitor by Escherichia coli.. Journal of Biological Chemistry. 261(16). 7115–7118. 44 indexed citations
15.
Anderson, Stephen K., Cara Marks, Robert A. Lazarus, et al.. (1985). Production of 2-Keto-L-Gulonate, an Intermediate in L-Ascorbate Synthesis, by a Genetically Modified Erwinia herbicola. Science. 230(4722). 144–149. 130 indexed citations
16.
Marks, Cara. (1983). Immunobiological determinants in organ transplantation.. PubMed. 65(3). 139–44. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026